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The aim of this study was to evaluate the effect of strontium ranelate (SrR) on bone mineral density (BMD) and bone
turnover markers after 1 year of treatment. Additionally, the effect of SrR in bisphosphonate-naïve patients (BP-naïve)
compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included
482 postmenopausal women treated with SrR (2 g/day) for 1 year in ten Argentine centers; 41 patients were excluded
due to insufficient data, while 441 were included. Participants were divided according to previous bisphosphonate
treatment in two groups: BP-naïve (n = 87) and BP-prior (n = 350). Data are expressed as mean ± SEM. After 1 year of
treatment with SrR the bone formation markers total alkaline phosphatase and osteocalcin were increased (p < 0.0001),
while the bone resorption marker s-CTX was decreased (p = 0.0579). Also increases in BMD at the lumbar spine (LS,
3.73%), femoral neck (FN, 2.00%) and total hip (TH, 1.54%) [p < 0.0001] were observed. These increments were significant
(p < 0.0001) both among BP-naïve and BP-prior patients. Interestingly, the change in BMD after 1 year of SrR treatment
was higher in BP-naïve patients: LS: BP-naïve = 4.58 ± 0.62%; BP-prior = 3.45 ± 0.28% (p = 0.078). FN: BP-naïve = 2.79 ±
0.56%; BP-prior = 2.13 ± 0.29% (p = 0.161). TH: BP-naïve = 3.01 ± 0.55%; BP-prior = 1.22 ± 0.27% (p = 0.0006). SrR treatment
increased BMD and bone formation markers and decreased a bone resorption marker in the whole group, with better
response in BP-naïve patients.
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Osteoporosis is a chronic condition characterized by de-
creased bone mass and deterioration of bone microarchi-
tecture; it compromises bone strength thus predisposing
to fragility fractures. Current available and worldwide
approved treatments for osteoporosis are antiresorptive
medications, which include bisphosphonates (BP), se-
lective estrogen-receptor modulators, calcitonin and
denosumab, and bone-forming agents, such as teriparatide
(PTH1–34) (Schurman et al. 2013). Strontium ranelate
(SrR) is widely used for the treatment of postmenopausal
osteoporosis (Galich 2011). Its mechanism of action is
dual, since on one hand it induces bone formation
(anabolic effect) while on the other hand it reduces the
rate of bone resorption (anticatabolic effect) (Bonnelye
et al. 2008). Its efficacy has been demonstrated in relatively* Correspondence: asanchez@circulomedicorosario.org
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patients with high fracture or refracture risk, in smokers,
and in men (Meunier et al. 2004, 2009; Reginster et al.
2005; Seeman et al. 2006; Kaufman et al. 2013). It has been
shown to be effective in reducing the incidence of
vertebral and non-vertebral fractures (Meunier et al. 2004;
Reginster et al. 2005).
SrR decreases osteoclast differentiation and activity
in vitro, as demonstrated by decrements of bone resorp-
tion markers but not bone formation markers in ovariec-
tomized rats (Marie et al. 1993). Additionally it induces
the disruption of osteoclast cytoskeleton and decreases
osteoclast resorbing activity (Takahashi et al. 2003). SrR
increases the production of osteoprotegerin (OPG) and
reduces the expression of receptor activator of nuclear
factor κB ligand (RANKL) in osteoblasts (Atkins et al.
2009; Brennan et al. 2009). It has been reported that OPG
is increased in postmenopausal women treated with SrR
as early as 3 months after initiation of treatmentOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Baseline clinical characteristics of all patients
(n = 441)
Basal
Age (years) 67.20 ± 0.50
Body mass index (kg/m2) 24.55 ± 0.18
Serum calcium (mg/dl) 9.36 ± 0.02
Urinary calcium (mg/24 h) 171.30 ± 5.20
Serum phosphate (mg/dl) 3.97 ± 0.03
25(OH) vitamin D (ng/ml) 32.04 ± 1.00
iPTH (pg/ml) 51.00 ± 3.11
tAP (IU/L) 59.70 ± 1.36
BGP (ng/ml) 17.02 ± 0.98
s-CTX (ng/l) 331.10 ± 16.03
Lumbar spine BMD [g/cm2; T-score] 0.859 ± 0.005; −2.75 ± 0.04
Femoral neck BMD [g/cm2; T-score] 0.718 ± 0.004; −2.29 ± 0.04
Total hip BMD [g/cm2; T-score] 0.747 ± 0.005; −2.17 ± 0.05
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lication of preosteoblasts, increases bone matrix synthesis
by preosteoblasts and osteoblasts (Canalis et al. 1996) and
increases mineralization (Choudhary et al. 2007). SrR in-
duces osteoblastogenesis by stimulation of both canonical
and noncanonical Wnt signaling pathways (Fromigué
et al. 2010). Accumulation of advanced glycation endpro-
ducts (AGEs) in bone tissue occurs in ageing and in diabetes
mellitus. It has been demonstrated that SrR can prevent the
deleterious in vitro actions of AGEs on osteoblastic cells in
culture by mechanisms that involve calcium channel,
MAPK and β-catenin activation (Fernández et al. 2013).
Significantly higher mineral apposition rate in cancellous
bone was observed by histomorphometry. Using μCT of
bone biopsies collected from humans receiving long-term
treatment with SrR over 5 years, increase in cortical thick-
ness and trabecular number has been demonstrated, with
no change in cortical porosity (Arlot et al. 2008). Also,
greater effects on distal tibia cortical thickness and trabe-
cular volumetric density were observed with SrR versus
alendronate over 2 years using HR-pQCT (Rizzoli et al.
2010).
Many osteoporotic women previously treated with BP
are prescribed SrR. Those patients who have adverse
effects of BP, or who maintain high fracture risk or have
poor treatment response to BP are of particular interest.
Middleton et al. have demonstrated that after treatment
with SrR the bisphosphonate-naïve group (BP-naïve) had
significantly greater bone mineral density (BMD) incre-
ments in spine, hip and heel (Middleton et al. 2010, 2012).
The aim of this study was to evaluate the effect of SrR
on BMD and bone turnover markers after 1 year of
treatment in clinical practice conditions in specialized
centers from Argentina. Additionally, the effect of SrR in
BP-naïve patients compared to patients previously
treated with bisphosphonates (BP-prior) was analyzed.
Patients and methods
This retrospective study analyzed records from 482 post-
menopausal women treated with SrR (2 g/day) for 1 year in
ten Argentine centers. All women had either a T-score of
less than −2.5 at the hip or spine or a T-score of less
than −2.0 and other risk factors for fracture. All patients
simultaneously received calcium (1000 mg/day) and
vitamin D (800 U/day). Women were excluded if they
had medical conditions or took medications associated
with bone disease. Participants were also analyzed
considering the previous use of BP; they were divided in
BP-naïve (n = 87) and BP-prior (n = 350) patients; 4
women were not included in this analysis because they
used other drugs besides BP.
Antrophometric parametes were considered: weight
(kg), height (m). Body mass index (BMI) was calculated
according to the formula: weight/height2 (kg/m2).BMD (g/cm2) was measured by dual-energy X-ray ab-
sorptiometry (DXA) GE Lunar Prodigy (GE Lunar, Madi-
son, WI, USA) in lumbar spine (L2-L4), femoral neck and
total hip. The coefficient of variation was less than 3% in
all centers where densitometries were performed.
Plasma calcium levels (mg/dl), plasma phosphate levels
(mg/dl) and total alkaline phosphatase (tAP, UI/L) were
spectrophotometrically measured. Serum parathyroid
hormone (iPTH, pg/ml) was measured by chemolumi-
niscent assay (iPTH Siemens Medical Solutions Diagnos-
tics). Total serum 25-hydroxyvitamin D levels [25(OH)
D, ng/ml] and serum carboxy-terminal crosslinking telo-
peptide of type I collagen (s-CTX, ng/l) were measured
by electrochemoluminiscent assay (Elecsys® Total Vita-
min D Roche, and Elecsys® ϐ-CrossLaps Roche Diagnos-
tics, respectively). Serum osteocalcin (BGP, ng/ml) was
determined by electrochemoluminiscent assay (Roche
Diagnostics). All measurements were not made in the
same place and by the same person, although the same
methods were used.
Data analysis
Data are expressed as mean ± SEM and were analyzed
with Mann–Whitney test or Wilcoxon signed rank test
as appropriate. Kolmogorov-Smirnov test for normality
was used to assess the distribution of the data. Differences
were considered significant if p < 0.05. Statistical analyses
were performed with GraphPad Prism 2.0 (GraphPad, San
Diego, USA).
Results
Subjects and baseline clinical characteristics
Medical records from 482 postmenopausal were ana-
lyzed; 41 patients were excluded due to insufficient data,
Figure 1 Increase of bone formation markers and decrease of a bone resorption marker after 1 year of treatment with SrR (*p < 0.05
vs basal).
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study population are shown in Table 1.
Change in bone markers with SrR
After 1 year of treatment with SrR, the bone formation
markers tAP (65.76 ± 1.57 UI/L) and BGP (22.93 ±
1.46 ng/ml) were significantly increased (Wilcoxon
signed rank test, p < 0.0001), with a mean increment of
10.15% and 34.72%, respectively. Meanwhile, the bone
resorption marker s-CTX (305.60 ± 16.31 ng/l) de-
creased by 7.7%, although this was not significant
(Wilcoxon signed rank test, p = 0.0579; Figure 1).
Change in BMD with SrR
After 1 year of treatment with SrR an increased BMD
at the lumbar spine (LS), femoral neck (FN) and total
hip (TH) was observed (Wilcoxon signed rank test, p <Figure 2 BMD increase at all sites after 1 year of treatment with SrR (0.0001). The percent change in BMD was: LS = 3.73 ±
0.26%, FN= 2.00 ± 0.24% and TH= 1.54 ± 0.24% (Figure 2).
Bisphosphonate-naïve vs prior bisphosphonate patients:
main characteristics
The patients were also analyzed considering the previous
use of BP; they were divided in BP-naïve (n = 87) and
BP-prior (n = 350) patients; 4 patients were not included
in this analysis because they used other drugs besides
BP. The duration of previous BP treatment was 5.35 ±
0.24 years. The age was higher in BP-prior group: BP-
naïve = 60.45 ± 1.12 years; BP-prior = 69.00 ± 0.56 (Mann
Whitney test, p < 0.0001). There were no significant dif-
ferences in BMI, years of menopause, serum calcium,
urinary calcium, serum phosphate, 25(OH)D and iPTH
between groups (data not shown).*p < 0.05 vs basal).
Table 2 Changes in bone markers after 1 year of SrR
treatment
BP-naïve p BP-prior p
tAP ↑ 4.4% 0.46 ↑ 10.7% 0.005
BGP ↑ 39.5% 0.08 ↑ 38.4% 0.002
s-CTX ↓ 10.8% 0.40 ↓ 12.7% 0.11
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As expected, basal BGP (but not tAP) was lower (p =
0.05) in the BP-prior group due to previous antiresorp-
tive treatment. After 1 year of treatment with SrR both
BPG and tAP, as bone formation markers, were increased,
particularly in the BP-prior group (BPG: BP-naïve: 39.5%
(p = 0.08); BP-prior: 38.4% (p = 0.002); tAP = BP-naïve:
4.4% (p = 0.46) and BP-prior: 10.7% (p = 0.005). Similarly,
basal s-CTX was lower (p = 0.005) in the BP-prior group.
After 1 year of treatment with SrR this bone resorption
marker was decreased; although this change was not
significant: BP-naïve: −10.8% (p = 0.40) and BP-prior:
−12.72% (p = 0.11) (Table 2).
Bisphosphonate-naïve vs prior bisphosphonate patients:
bone mineral density
The increments in BMD in the whole group at the LS, FN
and TH was also found both among BP-naïve and BP-prior
patients (Wilcoxon signed rank test, p < 0.0001; Figure 3).
Interestingly, the change in BMD after 1 year of
treatment with SrR was higher in BP-naïve patients: LS:
BP-naïve = 4.58 ± 0.62%; BP-prior = 3.45 ± 0.28% (Mann–
Whitney test, p = 0.078). FN: BP-naïve = 2.79 ± 0.56%; BP-
prior = 2.13 ± 0.29% (Mann–Whitney test, p = 0.161). TH:
BP-naïve = 3.01 ± 0.55%; BP-prior = 1.22 ± 0.27% (Mann–
Whitney test, p = 0.0006; Figure 3).
Discussion
The study evaluated the effect of SrR on BMD and bone
turnover markers after 1 year of treatment in clinicalFigure 3 A better response in BP-naïve patients was observed after 1practice conditions. A good response in BMD was
observed after 1 year of SrR treatment at all studied
regions: LS = 3.73%, FN = 2.00% and TH = 1.54%. Coinci-
dent with BMD changes, an increase of bone formation
markers and a decrease of the selected bone resorption
marker were found. Borderline changes in s-CTX (p =
0.0579) can be attributed to the wide dispersion of data.
When BMD was analyzed considering the previous
use of BP, a better response in BP-naïve patients was
observed, in accordance with previous papers. In agree-
ment with Middleton et al’s report (Middleton et al.
2010) our study found similar changes at the LS (4.58 vs.
5.6%) and TH (3.01 vs. 3.4%) in the BP-naïve group, and
also at the LS (1.22 vs. 0.8%) in the BP-prior group. Al-
though Middleton et al. did not find differences in TH
BMD values after 1 year of treatment with SrR, a signifi-
cant difference was observed in our study (p = 0.0006).
Besides, our study did not show a significant increase at
the LS in BP-naïve patients after 1 year of treatment, but
a borderline p value was found (p = 0.078). Middleton
et al. (Middleton et al. 2012) published data after 2 years
of treatment, where BMD increased significantly from
baseline in both groups, BP-naïve (LS = 8.9%; TH = 6.0%)
and BP-prior (LS = 4.0%; TH = 2.5%). When they com-
pared BP-naïve vs. BP-prior they found higher increments
among BP-naïve patients at 6 months of SrR treatment,
persisting after 24 months (Middleton et al. 2012). This
suggests that the differences found between our study and
Middleton et al’s (Middleton et al. 2010) could be the con-
sequence of differences in size and variability, and particu-
larly of longer treatment time with SrR, because after
2 years the differences become more evident.
There were differences in age between BP-naïve and
BP-prior women; however, it is unlikely that this could
have influenced the results: in the SOTI and TROPOS
studies the gain in BMD at the spine and the hip was of
the same magnitude among women 80 years or older
than in younger osteoporotic women (Seeman et al.
2006).year of treatment with SrR (*p < 0.05 vs basal).
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a mean gain in lumbar spine BMD that was greater in the
BP-naïve group (8.4%) than in patients pretreated with
antiresorptives with no evidence of inadequate treatment
response (7.1%), and in patients pretreated but showing an
inadequate response to antiresorptives (6.2%). Total hip
BMD increased from baseline in the BP-naïve (1.8%) but
no changes was observed in the groups BP-prior (−0.3%
and 0.4%) (Minne et al. 2008).
The use of BP reduces bone turnover leading to re-
duced new bone formation (Li et al. 2010) which could
reduce strontium uptake. However, markers of bone for-
mation were increased particularly in the BP-prior group
(Table 1). This is consistent with previous studies
(Middleton et al. 2010, 2012) and could indicate import-
ant changes in bone turnover due to its previous status
under antiresorptive treatment. Suppressed bone turn-
over could be the cause of a blunted response to SrR
treatment, but it seems to be reversed after 6 months ac-
cording to procollagen type 1 amino terminal propeptide
(P1NP) measurements (Middleton et al. 2012). However,
the BP-prior group could not reach the same values as
the BP-naïve group at least after 2 years of treatment
with SrR (Middleton et al. 2012).
Paired iliac crest biopsies from 15 patients previously
treated with BP suggest that SrR generates new bone
(Busse et al. 2010). This study found an increase in osteoid
surface and strontium content after 6 months of treat-
ment. After 12 months of SrR administration, there was a
significant increase in bone volume and trabecular thick-
ness, increased number of osteoblasts and osteoid surface
and volume.
There are limitations to this study. This was not a pro-
spective study, and BMD and bone markers were recorded
after 1 year without intermediate measurements. The wide
dispersion of some parameters could be due to the fact
that measurements were not made in the same place and
by the same person, although the same methods were
used. Also, the number of the BP-naïve women is not
similar to that of BP-prior women. This discrepancy could
influence the significance of results. Finally, it should be
considered that most of the women in the BP-prior group
were switched to SrR because of poor clinical response to
BP. There could be an undeterminate difference between
groups in the response to treatment.
In conclusion, SrR treatment increased BMD and
bone formation markers and decreased bone resorption
marker in the whole group with better response in BP-
naïve patients. Since there are no head-to-head studies
between BP and SrR comparing fracture risk reduction,
it is important to evaluate individual patients taking
into consideration expert guidelines either before
choosing the first treatment or before changing to a
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